IntroductionWe conducted this survey to explore what operative lung cancer patients knew about pulmonary rehabilitation and the factors that influence it.MethodsBetween 1 January 2018 and 31 December 2020, patients who received thoracic surgery were enrolled in this study. We used a three-part questionnaire to collect the clinical features and knowledge of pulmonary rehabilitation.ResultsA total of 93 patients were enrolled in this study. Most patients were female, ≤60 years old, had normal pulmonary function, and had been diagnosed with non-small-cell lung cancer. Univariate analysis revealed that patients with abnormal pulmonary ventilatory function, higher preoperative COPD assessment test (CAT) scores, higher CAT differences, and higher mMRC differences showed a higher awareness of pulmonary rehabilitation (p = 0.043, 0.029, 0.178, and 0.003, respectively). Multivariate analysis suggested that preoperative CAT score (p = 0.01) and mMRC difference (p = 0.001) were the factors associated with awareness of pulmonary rehabilitation.ConclusionMany factors may influence the patients’ knowledge of pulmonary rehabilitation. We found that a higher preoperative CAT score and a larger mMRC difference were factors associated with awareness of pulmonary rehabilitation. However, assistance should also be provided to patients who do not fall into these categories, as they may lack knowledge of pulmonary rehabilitation.

8525 Background: SHR-1826 is a novel ADC comprising a humanized IgG2 monoclonal antibody targeting c-MET, conjugated via a cleavable peptide-based linker to a topoisomerase I inhibitor payload. We conducted a multi-center, first-in-human, phase 1 trial of SHR-1826 in patients with advanced solid tumors. Here we report updated results, with a focus on patients with EGFR -mutated ( EGFRmut ) lung adenocarcinoma (LUAD). Methods: The study consisted of dose-escalation (i3+3 design), dose-expansion and efficacy-expansion phases. Patients with advanced solid tumors harboring MET alterations, who had failed standard therapy or had no available standard treatment options, were enrolled and received SHR-1826 intravenously at 2.2–6.0 mg/kg Q3W. In patients with EGFRmut LUAD, 4.0 and 5.0 mg/kg Q3W were evaluated during dose and efficacy expansion. Results: As of Dec. 3, 2025, 195 patients with lung (n=126), colorectal (n=40), gastric (n=22), liver (n=5), or pancreatic (n=2) cancer were treated. Median age was 59.0 yrs; 89.7% had ECOG performance status 1. Among 36 patients with EGFRmut LUAD, median number of prior lines of therapy was 2 (range 1–9); 97.2% had previously received EGFR-TKI (3 rd generation, 88.9%) and 75.0% received platinum-based chemotherapy. As of data cutoff, median follow-up was 14.4 months. Efficacy in EGFRmut LUAD across doses is shown in Table 1. Overall, the confirmed objective response rate (ORR) was 41.7% (95% CI 25.5–59.2) and median duration of response (DoR) was 14.1 months (95% CI 5.6–not reached [NR]). Median progression-free survival (PFS) was 9.8 mo (95% CI 5.8–15.4). Median overall survival (OS) was not reached; 12-month OS rate was 67.4% (95% CI 48.9–80.5). In all 195 patients, grade ≥3 treatment-related adverse events (TRAEs) were reported in 129 patients (66.2%), with all occurring in ≥5% being hematological toxicities. Interstitial lung disease occurred in 4 (3.1%; grade ≥3, n=2 [1.6%]) patients. TRAEs led to treatment discontinuation in 8 (4.1%) patients. No treatment-related deaths were reported. Conclusions: SHR-1826 demonstrated encouraging activity with manageable safety in heavily pretreated patients with MET-altered EGFRmut LUAD. Multiple trials are ongoing to assess SHR-1826 combined with other anti-tumor therapies in NSCLC. Clinical trial information: NCT06094556 . Efficacy outcomes in EGFRmut LUAD. 4.0 mg/kg (n=16) 5.0 mg/g (n=18) All patients (n=36) Confirmed ORR (n/N; 95% CI), % 31.3 (5/16; 11.0–58.7) 50.0 (9/18; 26.0–74.0) 41.7 (15/36; 25.5–59.2) DCR (n/N; 95% CI), % 87.5 (14/16; 61.7–98.4) 100.0 (18/18; 81.5–100.0) 94.4 (34/36; 81.3–99.3) Median DoR (95% CI), mo NR (8.6–NR) 9.7 (4.2–NR) 14.1 (5.6–NR) Median PFS (95% CI), mo 12.4 (2.6–NR) 8.4 (4.5–15.4) 9.8 (5.8–15.4) 12-mo OS (95% CI), % 67.0 (37.9–84.7) 69.1 (40.7–85.9) 67.4 (48.9–80.5) Data are based on the full analysis set. DCR, disease control rate.

BackgroundCircular RNAs (circRNAs) regulate cancer biology, but their relationships with parental genes remain unclear. We characterized circMPP6, derived from MPP6, and its interplay with MPP6 in non-small cell lung cancer (NSCLC).MethodscircMPP6 was validated by RNase R resistance and Sanger sequencing in A549 cells. Expression of circMPP6 and MPP6 was measured in 10 paired NSCLC tumors and adjacent-tissues. RNA-seq after gain-of-function of circMPP6, MPP6, and SLC7A11 was followed by enrichment analyses and chromosome-level DEG mapping. Proliferation was assessed by CCK-8 and xenografts. Lactate and glutathione were quantified, SLC7A11 protein measured by Western blot, and prognosis analyzed in GEO/TCGA.ResultsMPP6 trended upward in tumors, while circMPP6 was unchanged. circMPP6 and MPP6 were positively correlated in adjacent-tissues but not in tumors. Overexpression of circMPP6 and MPP6 yielded 765 and 334 DEGs, respectively, with shared enrichment of hypoxia-related pathways. 67 genes were upregulated by circMPP6 but downregulated by MPP6, also linked to hypoxia signaling. circMPP6-regulated DEGs were enriched on chromosome 19, whereas MPP6-regulated DEGs clustered on chromosome 17. Functionally, circMPP6 did not alter proliferation, MPP6 enhanced it, and co-expression attenuated MPP6-driven growth in vitro and in vivo. circMPP6 reduced intracellular lactate and glutathione; MPP6 minimally affected lactate and increased glutathione. Consistently, circMPP6 downregulated SLC7A11, whereas MPP6 upregulated it. High-risk circMPP6-driven signatures and high MPP6 expression associated with poorer prognosis.ConclusioncircMPP6 and MPP6 exert distinct, partially opposing effects on NSCLC growth. In the context of MPP6 overexpression, circMPP6 counteracts tumor-promoting programs, highlighting functional divergence between circRNAs and their parental genes.

Background:Chemotherapeutic treatments for advanced thymoma have limited efficacy and a high rate of adverse events, while it has been reported that glucocorticoids (GCs) may be effective in this context. This study aimed to retrospectively analyze the efficacy and safety of high-dose prednisone for patients with advanced thymoma in a single center in order to determine the optimal application scenarios for GCs in the treatment of these patients. Methods:Patients with previously treated advanced tumor-node-metastasis (TNM) (8th edition) stage III-IV thymomas that received treatment with high-dose prednisone (0.5-1 mg/kg/day) in Shanghai Chest Hospital were included. Clinical characteristics, response to prednisone, type of subsequent treatment, and adverse events were analyzed. Results:A total of 26 patients were included, with 15 (57.7%) having primary stage III-IV diseases and 11 (42.3%) having pleural recurrent stage IV diseases. The objective response rate (ORR) of prednisone was 57.7% (15/26), with 2 cases of complete response (CR) and 13 cases of partial response (PR). Ten (38.5%) patients had stable disease (SD), and 1 (3.8%) had progressive disease (PD). All patients had type B thymomas. The ORR was relatively higher in type B1 tumors than in the other subtypes (71.4% vs. 37.5%, P=0.19). Of the 26 patients, 16 (61.5%) received subsequent surgery and complete resection of the visible tumors, 5 (19.2%) received radiotherapy, 2 received long-term treatment of prednisone, and 3 were scheduled for follow-up. Three cases of pneumonia and one case of hypertension and diabetes were recorded during the treatment. After prednisone treatment, patients with PR or CR had significantly better progression-free survival (PFS) than did those with SD or PD (P=0.045). Conclusions:High-dose prednisone is effective and safe for the treatment of advanced thymoma. It might be particularly effective in induction therapy before surgery or in creating the opportunity for radiotherapy. The long-term administration of prednisone should be selected with careful consideration of its potential side effects.

e20171 Background: Thymic carcinoma (TC) is a rare and aggressive malignancy with poor prognosis in advanced stages. Given the limited efficacy of standard first-line regimen (carboplatin/paclitaxel), there remains an urgent unmet need for novel treatment approaches. This study evaluated the efficacy and safety of the PD-L1 inhibitor adebrelimab in combination with nanoparticle albumin-bound (nab)-paclitaxel and carboplatin as first-line therapy for advanced or recurrent TC. Methods: Patients (pts) with unresectable UICC stage III or IV, recurrent, or metastatic TCs without any previous anti-tumor therapy were enrolled.During the induction phase, pts received adebrelimab (20 mg/kg) plus nab-paclitaxel (260 mg/m 2 ) and carboplatin (AUC 5) every 3 weeks for up to 4-6 cycles. This was followed by the maintenance phase, adebrelimab (20 mg/kg) every 3 weeks for up to 2 years (including the induction phase), until progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR), and secondary endpoints included progression free survival (PFS), disease control rate (DCR), overall survival (OS), and safety. Results: Between August 15, 2023, and June 3, 2025, this study was conducted at two centers and enrolled a total of 37 pts. All pts were included in safety and efficacy analysis. The median age was 60.0 years old (range 29-71). A total of 26 pts (70.3%) pts completed the induction therapy and were transitioned to maintenance therapy while 11 pts (29.7%) remained on treatment at data cutoff (December 1, 2025). Four (10.8%) of 37 pts had complete response, 16 (43.2%) had partial response, and 17 (45.9%) had stable disease. The ORR was 54.1% (20/37) and DCR was 100% (37/37). The median PFS was 10.9 months (95% CI, 9.1-NA). Treatment-related adverse events (TRAEs) of any grade and of grade ≥3 severity occurred in 100% and 54.1% (20/37) of pts, respectively. The most common TRAEs were anemia, lymphocyte count decreased, and white blood cell count decreased. The immune-related AEs of grade ≥3 severity occurred in 16.2% (6/37) of pts, including immune-mediated rash, myositis and amylase increased. No grade 5 TRAEs were reported. Conclusions: Adebrelimab combined with nab-paclitaxel and carboplatin demonstrates promising efficacy and a manageable safety profile as first-line therapy for advanced or recurrent thymic carcinoma, offering a new potential treatment option for this patient population. Trial Registration: ChiCTR2300072705.

Background:In patients with unresectable lung adenocarcinoma, whether cross-line immunotherapy (CIT) can improve clinical outcomes remains unclear. Methods:This study enrolled patients with unresectable lung adenocarcinoma who received immune checkpoint inhibitors (ICIs)-based therapy and subsequently experienced disease progression. According to post-progression treatment strategies, patients were categorized into two groups: CIT group and Non-CIT group. The primary endpoints were second progression-free survival (PFS2), overall survival (OS), and post-progression survival (PPS), analyzed both using unadjusted and inverse probability for treatment weighting (IPTW) analyses. Survival outcomes were analyzed using the Kaplan-Meier method and compared with the log-rank test. Multivariate Cox regression was performed to identify independent prognostic factors. A nomogram for PPS prediction was built and internally validated with bootstrap resampling and receiver operating characteristic (ROC) curves. Results:A total of 185 patients met the inclusion criteria and were studied assessed, including 77 in the CIT group and 108 in the Non-CIT group. Baseline characteristics were generally balanced between two groups. After IPTW adjustment, median PFS2 was significantly longer in the CIT group compared with the Non-CIT group (6.3 vs. 2.8 months; hazard ratio (HR)=0.54, 95% confidence intervals (CI): 0.39-0.77, P<0.001). Similarly, the CIT group demonstrated improved median PPS and OS compared with Non-CIT group. Multivariate Cox analysis also identified CIT as independent predictors of PFS2, PPS and OS. The PPS nomogram showed good predictive performance. Conclusions:In patients with unresectable lung adenocarcinoma who progressed after initial immunotherapy, continuation of immunotherapy beyond progression was associated with significantly improved survival. The PPS nomogram may facilitate risk stratification and personalized post-progression management.

Extensive-stage small-cell lung cancer (ES-SCLC) is associated with a poor prognosis. Although first-line immunochemotherapy improves clinical outcomes, robust prognostic biomarkers for this treatment modality remain unavailable. The aim of this study was to identify non-invasive, easily accessible, and dynamically monitored biomarkers of ES-SCLC by machine learning integrating serum metabolomics, lipidomics, and proteomics at multiple time points. A total of 816 serum samples were collected from ES-SCLC patients receiving first-line immunotherapy combined with chemotherapy or first-line chemotherapy for metabolomics, lipidomics, and proteomics analysis. The immunochemotherapy cohort was randomly divided into training and validation subsets at a 6:4 ratio. Biomarkers were identified using machine learning algorithms, and their prognostic significance was evaluated through receiver operating characteristic (ROC) analysis, Kaplan–Meier survival analysis, and multivariate Cox regression. Potential metabolic pathways and mechanisms were further explored via integrated multi-omic analysis. The immunochemotherapy exhibited a prolonged median progression-free survival (PFS) and higher objective response rate (ORR) compared to the chemotherapy group. A total of 5 serum metabolites (uric acid, L-aspartate-semialdehyde, dimethisterone, xanthine, L-cysteine), 6 lipids (Cer d18:1/26:0, Cer d18:2/25:0, SM d18:1/20:1, SM d17:1/25:1, DG O-18:1_16:0, PS 18:0_24:0), and 3 proteins (ACIN1, ACSL4, PHGDH) were identified and constructed into independent prognostic models. Among patients receiving immunochemotherapy, those categorized as low-risk based on the model demonstrated significantly longer PFS compared with those in the high-risk group. These prognostic signatures also retained predictive value in patients who underwent second-line treatment with anlotinib plus immunochemotherapy. Integrated analysis revealed that glycine, serine, and threonine metabolism was the commonly enriched pathway across all three omics layers. Notably, PHGDH (protein), L-aspartate-semialdehyde and L-cysteine (metabolites), and PS (18:0_24:0) (lipid), key elements in this pathway, were all incorporated in the predictive model. In addition, models of the composition of these substances after one cycle of treatment can still predict the prognosis of patients. In this study, we constructed and validated a set of non-invasive, dynamically monitorable prognostic models (containing 5 metabolites, 6 lipids, and 3 proteins) using machine learning by integrating multiple time point data from the serum metabolome, lipid panel, and proteome to accurately distinguish the prognostic risk of patients with ES-SCLC receiving immunochemotherapy. PFS was significantly prolonged in patients in the low-risk group, and this model remains predictive in the subsequent second-line treatment with anlotinib in combination with immunochemotherapy. Glycine-serine-threonine metabolic pathway may be the key mechanism, of which PHGDH, L-aspartate semialdehyde, L-cysteine and PS (18:0_24:0) are the core predictors. This study provides the first multi-omics dynamic prognostic tool for ES-SCLC immunochemotherapy and reveals potential therapeutic targets.

8109 Background: With the limited efficacy of chemotherapy (carboplatin/paclitaxel) for advanced thymic carcinomas (TCs), better treatments are in need. In this study (ChiCTR2300072705), we evaluated the efficacy and safety of adebrelimab in combination with nab-paclitaxel and carboplatin as first-line treatment for unresectable advanced metastatic or recurrent TCs. Methods: In this study, patients with unresectable UICC stage III or IV, recurrent, or metastatic TCs without any previous anti-tumor therapy were enrolled. Patients were treated with adebrelimab (20 mg/kg) plus nab-paclitaxel (260 mg/m 2 ) and carboplatin (AUC 5) every 3 weeks for up to 4-6 cycles, followed by adebrelimab (20 mg/kg) every 3 weeks for up to 2 years until progression or unacceptable toxicity. The primary endpoint was the objective response rate (ORR). Secondary endpoints included progression free survival (PFS), disease control rate (DCR), overall survival (OS), and safety. A Simon two-stage design was applied. If more than 4 out of the first 18 pts achieved a response, the cohort would expand to include 33 pts, and the outcome would be considered positive if more than 10 pts achieved a response. Results: Between August 2023 and September 2024, 18 pts were enrolled in the first stage. All pts were included in the efficacy and safety analysis. The median age was 58.0 years old (range 29-71). At data cutoff (Dec 1, 2024), 9 pts (50.0%) were undergoing treatment. Discontinuations occurred in 5 pts (27.8%) primarily due to disease progression, 2 (11.1%) due to adverse events (AEs), 2 (11.1%) due to patient’s decision. Three (16.7%) of 18 pts had complete response, 9 (50.0%) had partial response, and 6 (33.3%) had stable disease. The ORR was 66.7% (12/18) and DCR was 100%. The median PFS was 10.2 months (95% CI, 8.8 - 11.6 months). AEs of any grade and of grade ≥3 severity occurred in 100% (18/18) and 61.1% (11/18) of pts, respectively. The most common treatment related AEs were white blood cell count decreased, neutrophil count decreased, and lymphocyte count decreased. The immune-related AEs of grade ≥3 severity occurred in 16.7% (3/18) of pts, including immune-mediated myositis, rash and lipase increased. None of the pts died from the treatment. Conclusions: In previously untreated advanced TCs, preliminary results showed that adebrelimab plus nab-paclitaxel and carboplatin is effective and safe. It provides a new treatment option in pts with advanced TCs. Clinical trial information: ChiCTR2300072705 .

106 Background: MET alterations are key drivers of diverse oncogenic processes, including tumor invasion, growth, and metastasis, and are associated with poor prognosis. SHR-1826 is a novel ADC of a humanized c-MET-directed IgG2 monoclonal antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. We conducted a multi-center, first-in-human, phase 1 trial of SHR-1826 in advanced solid tumors, and here report preliminary results from the dose-escalation and expansion portions. Methods: Patients (pts) with advanced solid tumors harboring MET alterations (overexpression, amplification, or activating mutation) who had failed standard therapy or no available standard therapy, were enrolled. The study consisted of dose-escalation (i3+3 design), dose-expansion and efficacy-expansion phases, during which pts received SHR-1826 at 2.2–6.0 mg/kg, Q3W, iv. Primary objectives were to assess safety and tolerability. Results: As of Dec.5, 2024, 116 pts were enrolled and treated (NSCLC/CRC/GC/PC, n=72/32/10/2; median age, 59.2 yrs; ECOG PS 1, 87.9%; ≥3 lines of prior therapy, 44.0%; median c-MET H-score, 163 [range 9-300]). During dose-escalation, 1 DLT was observed at 6.0 mg/kg (grade 3 febrile neutropenia). Grade ≥3 TRAEs were reported in 56 (48.3%) pts, with the most common being decreased neutrophil count (32.8%), decreased white blood cell count (22.4%), anaemia (13.8%), and decreased platelet count (11.2%). Interstitial lung disease occurred in 3 (2.6%; grade 1-2, n=2; grade 3, n=1) pts. 2 (1.7%) pts discontinued treatment due to TRAE. There were no treatment-related deaths. Among 58 evaluable pts with NSCLC, ORR was 39.7% (95% CI 27.0–53.4) and DCR was 94.8% (95% CI 85.6–98.9; Table 1); response was observed across a range of c-MET expression levels, and in both EGFR -mutated and wild-type tumors. Median duration of response was not reached, with 21 of 23 responses ongoing. In all 72 NSCLC pts, median progression-free survival was 6.8 mo (95% CI 4.5–7.2). Conclusions: SHR-1826 demonstrated a manageable safety profile in pts with heavily pretreated advanced solid tumors. Promising anti-cancer activity was observed in MET-altered NSCLC, warranting further investigation in this population. Clinical trial information: NCT06094556 . Efficacy in pts with NSCLC. 2.2 mg/kg (n=2) 4 mg/kg (n=24) 5 mg/kg (n=31) 6 mg/kg (n=1) All patients (n=58) Best overall response, n (%) Complete response 0 0 0 0 0 Partial response * 0 9 (37.5) 13 (41.9) 1 (100.0) 23 (39.7) Stable disease 2 (100.0) 14 (60.9) 16 (51.6) 0 32 (55.2) Progressive disease 0 0 2 (6.5) 0 2 (3.4) Not evaluable 0 1 (4.2) 0 0 1 (1.7) ORR * , % (95% CI) 0.0 (0.0–84.2) 37.5 (18.8–59.4) 41.9 (24.5–60.9) 100.0 (2.5–100.0) 39.7 (27.0–53.4) DCR, % (95% CI) 100.0 (15.8–100.0) 95.8 (78.9–99.9) 93.5 (78.6–99.2) 100.0 (2.5–100.0) 94.8 (85.6–98.9) Data are shown for pts with ≥1 post-baseline assessment. * Including 6 unconfirmed responses across groups.

N6-methyladenosine (m6A) serves as one of the crucial RNA modifications for genes involved in cancer progression. Here, 7273 expression quantitative trait loci potentially regulating 30 m6A pathway genes are identified from the GTEx database, with 69 single nucleotide polymorphisms significantly associated with survival of non-small cell lung carcinoma (NSCLC) patients (n = 1523) from the ongoing genome-wide association study after false positive probability tests. Notably, the rs151198415 locus, situated in a potential enhancer region, demonstrated a prolonged survival effect with the C>CCACG insertion, which is validated in an independent prospective cohort (n = 237), yielding a pooled hazard ratio of 0.72 (p = 0.007). Mechanistically, the rs151198415 C>CCACG insertion engaged in long-range interaction with the promoter of m6A eraser ALKBH5, promoting ALKBH5 transcription by the creation of an EGR1 binding site. Then, ALKBH5 upregulated FBXL5 expression by m6A demethylation, which is dependent on the ALKBH5 H204 amino acid site and specific m6A sites on FBXL5 mRNA. Finally, the ALKBH5-FBXL5 axis reduces intracellular reactive oxygen species levels, leading to PI3K/AKT and NF-kB pathway inhibition and consequently suppresses NSCLC proliferation and metastasis in vitro and in vivo. Triggered by an insertion variant, this remote cis-regulation of m6A eraser and the downstream molecular events modulate the survival of NSCLC patients.

BackgroundImmunotherapy has significantly advanced lung cancer treatment, particularly in nonsquamous non–small cell lung cancer (NSCLC), with overall response rates between 50% and 60%. However, about 30% of patients only achieve a stable disease state. Cryoablation has shown potential to enhance immunotherapy by modifying the tumor’s immune microenvironment through the release of antigens and immune factors. Addressing how to boost the immune response in these patients is critical. ObjectiveThis study aims to investigate the efficacy and safety of immunochemotherapy in combination with cryoablation as a first-line treatment for advanced NSCLC. MethodsThis is a phase II, pilot, open-label, single arm, single center, interventional study. Patients with stage IIIB to IIIC or IV NSCLC with T staging ranging from T1 to T2b will receive sintilimab (200 mg/m2 every 3 weeks) and chemotherapy. After 2 cycles, the feasibility of cryoablation will be considered for those with stable disease by a multidisciplinary team. Cryoablation with 3 freeze-thaw cycles will be performed for the main lesion. The third cycle of systemic therapy will begin 7 (SD 3) days after cryoablation. A total of 20 patients will be enrolled. Treatment will continue until the disease progresses, there is unacceptable toxicity, a participant withdraws consent, other discontinuation criteria are met, or the study reaches completion. The primary objective is to assess progression-free survival (PFS). The secondary objective is to assess efficacy through duration of response, disease control rate, overall survival (OS), and the safety profile. The exploratory objective is to investigate and compare immune factor changes after 2 cycles of immunochemotherapy and at 1, 3, and 7 days after cryoablation. Survival time will be estimated using the Kaplan-Meier method to calculate median PFS and OS. Any adverse events that occur during the trial will be promptly recorded. ResultsThe project was funded in 2024, and enrollment will be completed in 2025. The first results are expected to be submitted for publication in 2027. ConclusionsThis study will provide evidence for the efficacy and safety of the combination of immunochemotherapy and cryoablation as a first-line treatment for advanced NSCLC. Although it has a limited sample size, the findings of this study will be used in the future to inform the design of a fully powered, 2-arm, larger-scale study. Trial RegistrationClinicalTrials.gov NCT06483009; https://clinicaltrials.gov/study/NCT06483009 International Registered Report Identifier (IRRID)PRR1-10.2196/64950

AbstractBackgroundThe American Society of Clinical Oncology (ASCO) has strived to address racial/ethnic disparities in cancer care since 2009. Surgery plays a pivotal role in cancer care; however, it is unclear whether and how racial/ethnic disparities in cancer surgery have changed over time.MethodsThis cohort study included 1,113,256 White and Black cancer patients across 9 years (2007–2015) using patient data extracted from the Surveillance, Epidemiology, and End Results (SEER)‐18 registries. Patient data were included from 2007 to adjust insurance status and by 2015 to obtain at least a 3‐year survival follow‐up (until 2018). The primary outcome was a surgical intervention. The secondary outcomes were the use of (neo)adjuvant chemotherapy and cancer‐specific survival (CSS). Adjusted associations of the race (Black/White) with the outcomes were measured in each cancer type and year.ResultsThe gap between surgery rates for Black and White patients narrowed overall, from an adjusted odds ratio (aOR) of 0.621 (0.592–0.652) in 2007 to 0.734 (0.702–0.768) in 2015. However, the racial gap persisted in the surgery rates for lung, breast, prostate, esophageal, and ovarian cancers. In surgically treated patients with lymph node metastasis, Black patients with colorectal cancer (CRC) were less likely to receive (neo)adjuvant chemotherapy than White patients. Black patients undergoing surgery were more likely to have a worse CSS rate than White patients undergoing surgery. In breast cancer patients, the overall trend was narrow, but continuously present, with an adjusted hazard ratio (aHR) of 1.224 (1.278–1.173) in 2007 and 1.042 (1.132–0.96) in 2015.ConclusionsOverall, progress has been made toward narrowing the Black‐White gap in cancer surgical opportunity and survival. Future efforts should be directed toward those specific cancers for which the Black‐White gap continues. Additionally, it is worth addressing the Black‐White gap regarding the use of (neo)adjuvant chemotherapy for CRC treatment.

Background: Anlotinib is a novel anti-angiogenesis drug. In non-small cell lung cancer (NSCLC), high body mass index (BMI) was not associated with worse survival in patients treated with bevacizumab compared with those with normal or low BMI. However, it remains unknown whether such an association still exists in NSCLC patients receiving anlotinib therapy. Hence, we conducted this study to investigate whether BMI is associated with clinical outcomes in patients treated with anlotinib for advanced NSCLC. Methods: Data of 554 patients from the ALTER-0302 and the ALTER-0303 trials were analyzed in this study. The patients were classified into non-obesity (BMI <28 kg/m2) and obesity (BMI ≥28 kg/m2) subgroups. The primary endpoint was overall survival (OS). The secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). OS was defined as the interval between the first drug administration and death. PFS was defined as the time span from the date of initiating the treatment to the first documented progression or death from any cause, whichever occurred first. ORR included complete response (CR) and partial response (PR). Results: There were 354 patients (63.9%) who received anlotinib in this study. Restricted cubic spline model showed a U-shaped relation between BMI and the risk of death in the anlotinib group. In a multivariable Cox regression model, a trend of worse overall survival was observed in obese patients who received anlotinib compared with placebo (HR, 2.33; 95% CI, 0.77–7.06; p = 0.136). The interaction between BMI stratification and treatment was significant for OS (P for interaction = 0.038). Conclusion: Our results revealed a U-shaped relationship between BMI and risk of death in patients receiving anlotinib for advanced NSCLC. More importantly, obesity (BMI ≥28 kg/m2) might be a potential predictor of use of anlotinib in advanced NSCLC.

1Pulmonary and Critical Care Medicine, Shanghai Jiao Tong University, Shanghai Chest Hospital, Shanghai, People’s Republic of China; 2Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China; 3Department of Radiation Oncology, Shanghai Jiao Tong University, Shanghai Chest Hospital, Shanghai, People’s Republic of China

In this paper an optimization algorithm for time synchronization in telecommunication network is proposed based on VAE(Variational Auto Encoder)framework. Firstly features are represented in latent space under proposed framework while performance of synchronization network is measured and evaluated. Secondly optimization algorithm is further designed with which feature of abnormal samples and benchmark are adaptively merged for smooth adjustment with low risk in practical network operation. Meanwhile considering the characteristics as domain knowledge of synchronization network, a novel metric is adopted to reduce the fluctuation of adjustment. The simulation results verified that performance of synchronization network is significantly improved by optimization templates reconstructed through decoding part of VAE model. It is implied that prior knowledge of synchronization in latent space is introduced with certain interpret-ability for assessment of monitoring performance while optimization adjustment can be properly operated through novel metric proposed in this algorithm.

In this paper, a statistical analysis of peak-to-average power ratio (PAPR) for complex-value OFDM signals and real-value OFDM signals using differential coding (DC) is presented. DC-OFDM has the good performance of compressing intercarrier interference (ICI) at the cost of high PAPR. Adjacent partial transmit sequence (PTS) is a proper method to reduce the PAPR of DC-OFDM. The simulation results show that the theoretic analysis is very close to experimental result. The complex-value DC-OFDM system exhibits near 2dB PAPR higher than the same type normal OFDM. PTS with V=4 can reduce the PAPR of DC-OFDM to the normal complex-value OFDM level.